Results 91 to 100 of about 91,942 (288)

Primary Pulmonary Mesenchymal Neoplasm With EWSR1::CREM Fusion: Cytologic Findings and Molecular Diagnosis

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Background Primary pulmonary mesenchymal neoplasms with EWSR1::CREM fusion are rare. These lesions are challenging to diagnose by morphology and immunohistochemistry alone. Case A 66‐year‐old woman (ex‐smoker) was found to have a 1.3‐cm right lower lobe lung nodule that had grown very slowly over a 9‐year period.
Priya Upadhyay   +2 more
wiley   +1 more source

Cordycepin mediates neuroprotection against apoptosis via ERK/CREB signaling activation in Aβ1–42‐induced neuronal cell models

open access: yesIbrain, Volume 11, Issue 1, Page 84-97, Spring 2025.
This study demonstrates cordycepin's neuroprotective effects against Aβ1–42‐induced apoptosis in neuronal cells, mediated through the activation of the extracellular signal‐regulated kinase/cyclic AMP‐responsive element‐binding protein (ERK/CREB) signaling pathway.
Wenshu Zhou   +6 more
wiley   +1 more source

CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis

open access: yesAdvances in Hematology, 2009
The cAMP response element-binding protein (CREB) is a nuclear transcription factor downstream of cell surface receptors and mitogens that is critical for normal and neoplastic hematopoiesis.
Salemiz Sandoval   +2 more
doaj   +1 more source

Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism

open access: yes, 2002
International audienceCyclin D1, the regulatory subunit for mid-G(1) cyclin-dependent kinases, controls the expression of numerous cell cycle genes. A cyclic AMP-responsive element (CRE), located upstream of the cyclin D1 mRNA start site, integrates ...
Boulon, S.   +6 more
core   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons

open access: yesMolecular Neurodegeneration, 2011
Background Oxidative stress plays an important role in neuronal dysfunction and neuron loss in Alzheimer's brain. Previous studies have reported downregulation of CREB-mediated transcription by oxidative stress and Aβ.
Pham Serena   +4 more
doaj   +1 more source

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

open access: yesiNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong   +5 more
wiley   +1 more source

Acupuncture Activates ERK-CREB Pathway in Rats Exposed to Chronic Unpredictable Mild Stress

open access: yes, 2013
Extracellular signal-regulated kinase (ERK)-cAMP response element binding protein (CREB) signal pathway has been implicated in the pathogenesis of depression.
Tu, Ya   +5 more
core   +1 more source

Molecular Mechanisms of Memory: Identification and Modeling

open access: yes, 2009
(i) Understanding how memory is formed is an essential question in Neuroscience and is necessary to treat memory disorders, like Alzheimer’s disease.
MARASCO, ADDOLORATA
core  

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

open access: yesiNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy